Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.53T
24h Vol:
$11.53B
Dominance:
MSFT:5.18%
Stocklytics Platform
BETA
Instrument logo  VERA

Vera Therapeutics, Inc.

VERA
51 / 100
High Growth
$46.60arrow_drop_down-5.16%-$2.54

Performance History

Stocklytics logo
Key Stats
Open$49.51
Prev. Close$49.14
EPS-2.86
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.52B
PE Ratio-
LOWHIGH
Day Range46.21
50.02
52 Week Range5.95
50.78
Ratios
P/B Ratio21.33
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-15.40%
EBITDA Margin %-
ROE %-89.59%
EPS-2.86

Score Breakdown

51vs 53. Market Avg.

All Score 51 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

VERAMARKET
Value1339
Quality2540
Ownership4219
Growth8446
Dividends-37
check_circle

Vera Therapeutics, Inc.'s Price growth average in the last 3 years of 212.19% is great compared to market average of 8.28%. This indicates VERA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$794.98
24H (%)arrow_drop_up1.64%
24H ($)$12.86
MARKET CAP$755.62B
PRICE$482.50
24H (%)arrow_drop_down-1.43%
24H ($)-$7.03
MARKET CAP$446.34B
PRICE$159.68
24H (%)arrow_drop_down-1.50%
24H ($)-$2.44
MARKET CAP$384.41B
PRICE$123.72
24H (%)arrow_drop_down-2.54%
24H ($)-$3.23
MARKET CAP$313.35B

About Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Marshall Fordyce M.D.
Headquarters
Brisbane
Employees
49
Exchange
NASDAQ
add Vera Therapeutics, Inc. to watchlist

Keep an eye on Vera Therapeutics, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Vera Therapeutics, Inc.'s (VERA) price per share?

The current price per share for Vera Therapeutics, Inc. (VERA) is $46.6. The stock has seen a price change of -$2.54 recently, indicating a -5.17% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Vera Therapeutics, Inc. (VERA)?

For Vera Therapeutics, Inc. (VERA), the 52-week high is $50.78, which is 8.97% from the current price. The 52-week low is $5.95, the current price is 683.19% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Vera Therapeutics, Inc. (VERA) a growth stock?

Vera Therapeutics, Inc. (VERA) has shown an average price growth of 212.19% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vera Therapeutics, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Vera Therapeutics, Inc. (VERA) stock price performance year to date (YTD)?

As of the latest data, Vera Therapeutics, Inc. (VERA) has a year-to-date price change of 198.24%. Over the past month, the stock has experienced a price change of 25.91%. Over the last three months, the change has been 235.98%. Over the past six months, the figure is 150.4%.

question_mark
Is Vera Therapeutics, Inc. (VERA) a profitable company?

Vera Therapeutics, Inc. (VERA) has a net income of -$102.77M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$108.56M. Furthermore, the EBITDA is $0.

question_mark
What is the market capitalization of Vera Therapeutics, Inc. (VERA)?

Vera Therapeutics, Inc. (VERA) has a market capitalization of $2.5B. The average daily trading volume is 1.01M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.